Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...
Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...
From Nylon to Neural Networks Defining the Landscape The Hawthorne Effect in the Bathroom Manual Toothbrush vs.
Breakthrough AI foundation model called BrainIAC is able to predict brain age, dementia, time-to-stroke, and brain cancer ...
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of liver disease worldwide, affecting one in three people.1,2 The inflammatory form of MASLD, namely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results